Member Info for kentan

They have announced that they will issue new 115,211,604 ordinary shares at £0.0021 to its Executive Chairman, Law Chung Lam Nelson, in partial repayment of his loan, amounting to £241,944 ... this will increase the total shareholding of the company to 715,815,080 ordinary shares when admitted to trading on January 5th 2023.
So he will then own a huge share of the company once these shares are added to his existing holding on the register, plus the remainder of his loan of around £750k, more akin to a private company with his majority holding.
Is this for the better or worse? .... It doesn't add to the working capital.
Maybe he is expecting a huge rise in the capital worth of the company and wants to have a share in it.

The Chairman/CFO would say that, he has nearly £1m invested of his own money ... but I take it is reassuring that he is using his own money.
Disappointed that they had to issue more stock to pay for the expenses, it was only a paltry sum compared to the market value of the company.
What has happened to the JV market "fish maw" collaboration set up nearly 2 years ago? ... After encouraging reports of massive interest and projected sales, there has been silence ever since ... or was it just to ramp up the SP?
I want this company and its ventures to succeed, for my benefit and for other shareholders, but it worries me that there are false dawns and evidence of pump-and-dump transactions that hardly give confidence.

The interim results published on 27th September 2022 for the 6 months to 30th June 2022 hardly reflect the upbeat sentiment expressed by a few rampers on here who quote positive liquidity and profitable prospects for the near future.
Quote:
Going Concern:

As at 30 June 2022, the Group has cash and cash equivalent balances of £13,031 and net current liabilities and net liabilities of £1,258,755.
The directors' cash-flow projections for the forthcoming 12 months conclude there will be a need for additional cash resources. The directors are in discussions with some parties that may raise further equity and/or loans. There is no certainty that any such funds will be forthcoming or the price and other terms will be acceptable.

Financial Review:
During the six months ended 30 June 2022, the loss attributable to ordinary shareholders was £226,910 (2021: £98,643), and the revenue for the period was £76,071 (2021: £39,184). The loss has widened because of an accrual of director's fees of £99,000 (the considerable majority of which have not been paid) and an issue of shares valued at £27,000 to settle some professional fees.
My view:
If the directors decided to take their fees, then the loss would be even greater and we know the Chairman has invested his own money to keep the company afloat (now quoted as £830,959). Without that, it would have gone bust.
They say prospects are good for increasing sales as e-commerce continues to grow, the home confinement from continuing Covid restrictions adds to this, but the adverse effect on the economy will eventually filter through and make luxury purchases decline in volume ... look at how it has affected the Western economies.
I have a substantial holding (pre Covid) that has dwindled from previous expectations, with the further prospect of dilution ... so the future is not as rosy as some paint.

The current political situation in China is causing concern for investors, with students and activists rioting in the streets and human rights being questioned (even by our PM at the Lord Mayor's banquet at The Guildhall).
This must be having a serious knock-on effect on any Chinese-related investments, with those also speculating on a recovery to SP's once the tensions subside.
It is a dangerous game to play if the investment does not have the funds in place to survive.
Good luck to those taking the gamble.

edited out part should read: v*xm*rk*ts ... once you add the vowels.
It seems very petty that LSE should do this.

The results announced yesterday in the Arcadia trials (thankfully nothing to do with Sir Philip Green) further augment what was said in this article dated 7th March ... https://www.**********.co.uk/articles/-cizzle-biotechnology-notes-positive-data-from-azd1656-study-ddb6de2/ ... although the study was limited to those with underlying health issues, namely diabetes, there is encouragement that a rollout of AZD 1656 (originally developed by Astra Zeneca) in its modified form could benefit other sufferers of Covid 19 with underlying health problems and a ****tail of treatments could evolve to further enhance the results with time. The same thing happened with the AIDS treatment formulas to great effect. As CIZ is the beneficiary of a royalty revenue stream for its 5% investment and most of the R&D has been completed there is a good return in prospect for those that are patient ... marketing and pricing being the optimum for an in-demand product, especially in the third world where vaccination has have been sparse.

It is too early to say ...
There are many more hurdles to cross, but this is a good start.
It shows the science is on the right track and in a very short term they should have a marketable safe product that passes all the regulatory requirements.

This is what I posted on CIZ Telegram Group and Vela (LSE site):
At the 21 day stage of the trial:
Of the 153 who underwent the treatment trial using AZD 1656, split between 80 on the drug and 73 on the placebo ... only 1 died who had been administered AZD 1656, while 6 of those of the lesser number on the placebo, unfortunately, passed away ... that surely shows a remarkable outcome to the preliminary clinical trial.
In the results of the extended trial (28 days), the mortality rates were still in favour of using AZD 1656 with 4 deaths out of 80 (5%) and 9 out of 73 (12.33%) for those on the placebo. In all cases, using the drug resulted in lower hospitalization times for those who survived and a markedly lower adverse reaction = 10/84 (11.9%) on AZD 1656, whereas 19/69 (27.54%) on the placebo were affected. ... there is still work to be done to minimize the adverse reactions, but this should come in time once the medication dosage can be tweaked and supplementary medicine combined to help.
It is a very detailed report that shows favourable outcomes in nearly all of the categories.
CIZ can be well pleased.

This is what I posted on CIZ Telegram Group:
At the 21 day stage of the trial:
Of the 153 who underwent the treatment trial using AZD 1656, split between 80 on the drug and 73 on the placebo ... only 1 died who had been administered AZD 1656, while 6 of those of the lesser number on the placebo unfortunately passed away ... that surely shows a remarkable outcome to the preliminary clinical trial.
In the results of the extended trial (28 days), the mortality rates were still in favour of using AZD 1656 with 4 deaths out of 80 (5%) and 9 out of 73 (12.33%) for those on the placebo. In all cases using the drug resulted in lower hospitalisation times for those who survived and a markedly lower adverse reaction = 10/84 (11.9%) on AZD 1656, whereas 19/69 (27.54%) on the placebo were affected. ... there is still work to be done to minimise the adverse reactions, but this should come in time once the medication dosage can be tweaked and supplementary medicine combined to help.
It is a very detailed report that shows favourable outcomes in nearly all of the categories.
CIZ can be well pleased.

https://www.asgam.com/index.php/2021/10/26/macau-grand-prix-confirmed-to-proceed-in-november/
A slimmed-down Carnival Weekend motor racing spectacle is being held during November with only F4 car racing by FIA, this is because of the 21-day quarantine rules that are being implemented in the region, so restricting the usual overseas participation and its attraction to those who also come for the many Gaming Casinos ... remember Macau is China's "Las Vegas" with high profile and huge turnover in the past which is very lucrative for all the sponsors and the Govt.

I am pleased to see further additions of luxury products to the SCGL portfolio and the far-sighted use of the social media buying platforms, these products are not high volume but have high margins to reward sales exposure with the use of inspirational "web influencers" ... so long as the supply chain can be maintained.
With the recent generous granting of share options, I am now looking for the annual "bump-up" in share value to benefit those in the know.

Today they have announced an issue of 77.8m shares at 0.07p to the Chairman, Nelson Law, in respect of repayment of part of the loan of £1m he made to the company from his own funds.
This shows further commitment on his part and shows his confidence in the future of the company with the prospect of the increase in the share price will ensure an appreciable return on capital (if the loan wasn't aligned to the share price then it would not increase in value).
Although the issue of equity dilutes the share value in the short term, there is good reason to expect a further rise from a low level that seems to occur around this time every year once a director or insider has acquired an increased stake ... maybe considered to be insider trading, but it happens all the time these days.
News of acquisitions and joint ventures can be expected in the next few weeks and the recent news that Alibaba is making inroads into the European online shopping markets with further upbeat news in the pipeline can only strengthen the
e-market in which SCGL operates.
Could be the time to increase holdings before the next anticipated spike in the SP.

The addition of the exclusive rights to distribute Heath London men's grooming products in China is a very positive move by SCGL that should appeal to the upmarket Chinese consumer.
The 2018 founded company has created a niche market in the UK by restricting its outlets to premium department stores Selfridges, Fortnum & Mason and a recent deal with Boots to stock their products in 150 stores & online.
I would expect to see its grooming products in Liberty, Harrods & Harvey Nichols alongside other upmarket brands like "Creed" & "Comme De Garcon" that the Chinese tourists in London load up with to take back home ... any chance to supply any of the recognised brands on e-shopping-malls in the Far East must be a winner.
Let us hope the supply chain isn't affected by what is going on at the moment.

The addition of the exclusive rights to distribute Heath London men's grooming products in China is a very positive move by SCGL that should appeal to the upmarket Chinese consumer.
The 2018 founded company has created a niche market in the UK by restricting its outlets to premium department stores Selfridges, Fortnum & Mason and a recent deal with Boots to stock their products in 150 stores & online.
I would expect to see its grooming products in Liberty, Harrods & Harvey Nichols alongside other upmarket brands like "Creed" & "Comme De Garcon" that the Chinese tourists in London load up with to take back home ... any chance to supply any of the recognised brands on e-shopping-malls in the Far East must be a winner.
Let us hope the supply chain isn't affected by what is going on at the moment.

Very disconcerting to see Harvey Nichols tie -in is misspelled on more than one occasion in the interim unaudited accounts to 30th June 2021 ... referred to as "Harvey Nicols" ... surely the accountants and publishers of this record would have noticed the mistake ... unless this Harvey Nicols (Hong Kong) is a clone company with no connection to the UK brand and is meant to mislead ... would have thought HN lawyers would have been on the case if it is.
Under the "Going Concern" heading, following the Covid impact, there now exists a significant liability (deficit) and it is said it is inevitable that substantial fundraising would be required to develop the business and maintain day-to-day cash flows ... we note that the Chairman (in the recent past) has put in substantial amounts of his own money, so he is committed to continue growing the business.
From what I can see from the mention of the remaining Hydrax Holdings acquisition it amounts to nothing more than "chicken feed" as a contributor to funds. ... Are they responsible for the distribution and sale of Fish Maw? ... strangely there is no mention of the product after the bullish statements made a year ago of huge demand and increased markets for the niche Chinese foodstuff, which would not necessarily be affected by the Covid pandemic provided the countries where it is sourced are able to supply.
As we are experiencing in the UK, maintaining the supply chain is a major concern and this must be a worry for all retailers in the Asian market too who have high overheads for outlets and staff ... but this is where this impact can be minimised by internet sales and by not keeping high stock inventories, provided the demand can be met ... this is where SCGL can prosper in a competitive marketplace.

In the past 3 years, there has always been the most activity and rise in the share price during late October through to November.
This is when they announce new contracts and JV's and give favourable updates on the existing business.
Prior to this, the SP drifts down and a few insiders top up their shareholdings.
Looks to be following the same scenario this year ... the report in July stated that despite Covid the margins and turnover were still increasing but at a lower level.

"Honey Trap"
Big spread .... especially on bread!

From today's promising RNS there is plenty of interest in honey sales in China, renowned for use in its herbal and therapeutic remedies which the Chinese crave for.
https://marketingtochina.com/honey-market-shares-china/
Gives a good insight into the honey market, with the highly prized (and priced) Manuka Honey from New Zealand being the most appreciated.
Perhaps a Manuka Honey producer will be encouraged to market their product via SCGL.

That is now shown as a sell when it was a buy ...
as is my top up yesterday:
11/08/2021 09:54:48 18,818 shares @ 53.14p for £10k
This feature should be dropped if it is so inaccurate and misleading.

My purchase of 9,298 shares at 53.77p for £5k timed at 12:23 on 10th August 2021 is still not shown in the reported trades of yesterday.
Never trust the buys/sells reported, they are very misleading and inaccurate.

Although this is good news, the RNS amounts to no more than "Name Dropping" identifiable known upmarket brands with no mention of how they will monetise the opportunity. If it contained projections of an income stream there might be more interest from investors who are currently balking at the 11.%+ spread on the share price.
We also have to take into account how the Chinese Authorities' control of Hong Kong now affects the luxury market there, with any punitive taxes they may introduce in the near future on luxury goods the wealthy locals crave for.
MM's are still manipulating the price to mop up stock on the drops ... interesting to see if there are any late reported trades.